| Literature DB >> 35059330 |
Marco Capece1, Marco Falcone2, Tommaso Cai3, Alessandro Palmieri1, Andrea Cocci4, Roberto La Rocca1.
Abstract
Ischemic priapism accounts for more than 95% of all priapic episodes. It has to be considered a urological emergency because its time extension may lead to necrosis of smooth muscle cells of the corpora cavernosa, resulting in a complete erectile dysfunction, penile shortening and loss of girth. In the present systematic review, we perform an up-to-date literature search for patients suffering from refractory ischemic priapism who undergo penile prosthesis implantation with particular interests to the patients characteristics. The conservative management of the priapic episode consists of a sympathomimetic agent in the first istance. Failure or recurrence of priapism following these conservative measures is an indication for surgical management. Shunt procedures between the corpora cavernosa and the neighbouring structures are often used first line; however, in refractory ischemic priapism the success rate is minimal. In such cases (>48 h) an indication of immediate placement of a penile prosthesis could be the best solution.Entities:
Keywords: erectile dysfunction; penile prosthesis; priapism; refractory ischemic priapism
Year: 2022 PMID: 35059330 PMCID: PMC8765601 DOI: 10.2147/RRU.S278807
Source DB: PubMed Journal: Res Rep Urol ISSN: 2253-2447
Figure 1PRISMA flow-chart.
Studies Focusing on Penile Prosthesis Implantation After Refractory Ischemic Priapism
| Study | Design | Patients (n) | Etiology of RIP | Age (Years) | Ethnicity | Duration of Priapism (Hours) | Implant |
|---|---|---|---|---|---|---|---|
| Upadhyay et al, | CR | 1 | SCD | 19 | African-American | N/A | IPP |
| Rees et al, | RS | 8 | 3 Idiopathic 1SCD, 3 ICI, 1 Psychotropic drug | Mean 41 (Range 27–58) | N/A | Median 91 (range 32–192) | 2 IPP, 6 MPP |
| Tausch et al, | CR | 1 | SCD | 68 | African-American | 26 | MPP |
| Ralph et al, | RS | 50 | 24 idiopathic, 6 antidepressants, 5 SCD, 4 PDE5i, 4 ICI, 2 recreational drugs, 2 α-blockers, 1 epilepsy, 1 β-thalassemia, 1 prostate cancer | Mean 46 (Range 25–73) | N/A | Median 209 (Range 24–720) | 43 MPP, 7 IPP |
| Salem and El Aasser, | RS | 12 | 6 ICI, 4 idiopathic, 1 SCD, 1 PDE5i | Mean 43 (Range 28–56) | N/A | Median 120 (Range 60–168) | 12 MPP |
| Sedigh et al, | RS | 5 | NA | Mean 52 (Range 33–73) | N/A | Median 41 (Range 25–72) | 1 MPP, 4 IPP |
| Faddan et al, | CR | 1 | Idiopathic | 53 | N/A | 29 | MPP |
| Tausch et al, | RS | 14 | 4 SCD, 3 drug-induced, 7 idiopathic | N/A | N/A | Mean 82 | 14 MPP |
| Zacharakis et al, | RS | 10 | 4 idiopathic, 3 drug-induced (trazodone), 2 SCD, 1 ICI | Mean 41.3 (Range 26–58) | N/A | Median 188 (Range 98–336) | 10 MPP |
Abbreviations: CR, Case Report; RS, Retrospective Study; SCD, Sickle Cell Disease; ICI, Intracavernosal injection; MPP, Malleable Penile Prosthesis; IPP, Inflatable Penile Prosthesis.